BRAF and neoplasm: Conversely, RAF dimer inhibitor monotherapy (e.g., LY3009120) results in paradoxical ERK activation in BRAF WT tumor cells due to the formation of RAF heterodimers (Lito et al. 2014; Peng et al. 2015; Lai et al. 2022).